Although the medical relevance of the aforementioned cardiovascular possibility factor alterations by tirzepatide will likely be assessed within the prepared cardiovascular consequence examine SURPASS-CVOT ( "form":"clinical-trial","attrs": "text":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Assessment ind